COMPOUNDING SUBCOMMITTEE

Amy Gutierrez, PharmD, Chairperson
Randy Kajioka, PharmD, Board Vice-President

FOR DISCUSSION:
Over the years the board has developed and refined regulations that govern the practice of compounding and sterile injectable compounding by a pharmacy. Although conversation in this area has been ongoing, a more thorough and comprehensive discussion and review is warranted in light of recent public health issues.

The board’s public protection mandate specifies that protection of the public shall be the highest priority for the board in exercising its licensing, regulatory, and disciplinary functions. Since the beginning of October 2012, the country has become aware of the dangers contaminated compounded medication pose to the public health.

In California, existing law requires either an additional specialty license issued by the board or specific accreditation for any pharmacy that compounds sterile injectable products within, or ships such products into, California. These statutory requirements were developed in 2001 following the deaths of three patients in the Bay Area who had received injections of contaminated compounded medication. Following this enactment, the board has developed regulations that sterile injectable compounding pharmacies must follow whether specially licensed with the board or whether accredited. The board has also developed regulation requirements for any pharmacy that does general compounding.

In June 2012, the board issued a cease and desist order to a California-licensed nonresident sterile injectable pharmacy located in Florida because it had shipped contaminated product into California. Issuing such a cease and desist order is an act authorized in the 2001 legislation. In October, the board issued another cease and desist order against the California-licensed New England Compounding Center once it was confirmed they had shipped potentially contaminated product into California and contaminated products into other states.

The more recent emergency involving the New England Compounding Center and the pharmacy in Florida that distributed contaminated sterile injectable product to California physician offices requires that the board reevaluate its regulation program in this area to ensure it provides optimal public protection.

Since late October 2012 the board has issued three additional cease and desists orders – two pharmacies, and one pharmacist for violations involving sterile injectable compounding.
During both the October and December 2012 board meetings, the board discussed these incidents where consumers were harmed because of compromised compounded drug product. The results of these discussions yielded both a legislative proposal that will be sponsored by the board this year as well as the creation of a new compounding subcommittee.

Since the last board meeting President Weisser appointed Dr. Gutierrez and Dr. Kajioka to serve on this committee. There has been no public meeting of this committee yet.

Also in mid December, Executive Officer Herold attended an FDA forum on compounding practices at the state level. Representatives from all 50 states were present and asked to provide comments on four inquiries regarding compounding; specifically:

- Given existing authorities and resources, are the states currently able to provide the needed oversight of pharmacy compounding and consumer protection?
- What should the federal role be in regulating higher-risk pharmacy compounding such as compounding high volumes of drugs for interstate distribution?
- Is there a way to rebalance federal and state participation in the regulations of pharmacy compounding that would better protect the public health? What strategies should be developed to further strengthen federal/state communications?
- Do you see a role for the states in enforcing a feral standard for “non-traditional” compounding? If so, what role? What factors would affect a decision by your state to take on such responsibility?

We do not believe that FDA has released its response to the comments provided yet.

**Update**

In early January 2013, Board Members Gutierrez and Kajioka discussed with staff topics for the subcommittee’s review. During this meeting, the subcommittee members were updated on the status of board-sponsored legislation that will strengthen the board’s regulation over pharmacies that compound sterile drug products. Subcommittee members requested that staff prepare a comparison of the board’s current regulations versus the compounding requirements of USP 797. In addition the subcommittee requested an analysis of the board’s inspection findings of pharmacies that compound sterile injectable products as well as a comparison of the licensure requirements with other states. Work on these items is ongoing and should be completed in advance of the first public subcommittee meeting, which will be convened before the April 2013 board meeting.
REFERENCES (Attached):

- **California Statutes**
  Business and Professions Code, Chapter 9, Division 2, Article 7.5 establishes the licensing requirements for pharmacies that compound sterile injectable products as well as the board’s authority to regulate such entities.

- **Board Regulations**
  Title 16 California Code of Regulations, Division 17, Article 4.5 establishes the requirements governing general compounding.

  Title 16 California Code of Regulations, Division 17, Article 7 establishes the requirements for sterile injectable compounding

- **Pending Revisions**
  Title 16, California Code of Regulations, Division 17, Title 16, Articles 4.5 and 7

  Proposed amendments to Business and Professions Code, Chapter 9, Division 2, Article 7.5 to modify existing sterile injectable compounding licensure requirements.
AGENDA ITEM XII

ATTACHMENT 1
4127. Board Shall Adopt Regulations Establishing Standards
The board shall adopt regulations establishing standards for compounding injectable sterile drug products in a pharmacy.

4127.1. License to Compound Injectable Sterile Drug Products Required
(a) A pharmacy shall not compound injectable sterile drug products in this state unless the pharmacy has obtained a license from the board pursuant to this section. The license shall be renewed annually and is not transferable.
(b) A license to compound injectable sterile drug products may only be issued for a location that is licensed as a pharmacy. Furthermore, the license to compound injectable sterile drug products may only be issued to the owner of the pharmacy license at that location. A license to compound injectable sterile drug products may not be issued until the location is inspected by the board and found in compliance with this article and regulations adopted by the board.
(c) A license to compound injectable sterile drug products may not be renewed until the location has been inspected by the board and found to be in compliance with this article and regulations adopted by the board.
(d) Pharmacies operated by entities that are licensed by either the board or the State Department of Public Health and that have current accreditation from the Joint Commission on Accreditation of Healthcare Organizations, or other private accreditation agencies approved by the board, are exempt from the requirement to obtain a license pursuant to this section.
(e) The reconstitution of a sterile powder shall not require a license pursuant to this section if both of the following are met:
(1) The sterile powder was obtained from a manufacturer.
(2) The drug is reconstituted for administration to patients by a health care professional licensed to administer drugs by injection pursuant to this division.
(f) This section shall become effective on the earlier of July 1, 2003, or the effective date of regulations adopted by the board pursuant to Section 4127.

4127.2. Nonresident Pharmacy – License to Compound and Ship Injectable Drug Products into California Required
(a) A nonresident pharmacy may not compound injectable sterile drug products for shipment into the State of California without a license issued by the board pursuant to this section. The license shall be renewed annually and shall not be transferable.
(b) A license to compound injectable sterile drug products may only be issued for a location that is licensed as a nonresident pharmacy. Furthermore, the license to compound injectable sterile drug products may only be issued to the owner of the nonresident pharmacy license at that location. A license to compound injectable sterile drug products may not be issued or renewed until the board receives the following from the nonresident pharmacy:
(1) A copy of an inspection report issued by the pharmacy's licensing agency, or a report from a private accrediting agency approved by the board, in the prior 12 months documenting the pharmacy's compliance with board regulations regarding the compounding of injectable sterile drug products.
(2) A copy of the nonresident pharmacy's proposed policies and procedures for sterile compounding.
(c) Nonresident pharmacies operated by entities that are licensed as a hospital, home health agency, or a skilled nursing facility and have current accreditation from the Joint Commission on Accreditation of Healthcare Organizations, or other private accreditation agencies approved by the board, are exempt from the requirement...
to obtain a license pursuant to this section. (d) This section shall become effective on the earlier of July 1, 2003, or the effective date of regulations adopted by the board pursuant to Section 4127.

4127.3. Cease and Desist Order; Hearing
(a) Whenever the board has a reasonable belief, based on information obtained during an inspection or investigation by the board, that a pharmacy compounding injectable sterile drug products poses an immediate threat to the public health or safety, the executive officer of the board may issue an order to the pharmacy to immediately cease and desist from compounding injectable sterile drug products. The cease and desist order shall remain in effect for no more than 30 days or the date of a hearing seeking an interim suspension order, whichever is earlier.
(b) Whenever the board issues a cease and desist order pursuant to subdivision (a), the board shall immediately issue the owner a notice setting forth the acts or omissions with which the owner is charged, specifying the pertinent code section or sections.
(c) The order shall provide that the owner, within 15 days of receipt of the notice, may request a hearing before the president of the board to contest the cease and desist order. Consideration of the owner’s contest of the cease and desist order shall comply with the requirements of Section 11425.10 of the Government Code. The hearing shall be held no later than five days from the date the request of the owner is received by the board. The president shall render a written decision within five days of the hearing. In the absence of the president of the board, the vice president of the board may conduct the hearing permitted by this subdivision. Review of the decision of the president of the board may be sought by the owner or person in possession or control of the pharmacy pursuant to Section 1094.5 of the Code of Civil Procedure.
(d) Failure to comply with a cease and desist order issued pursuant to this section shall be unprofessional conduct.

4127.4. Fine for Violation
Notwithstanding any other provision of law, a violation of this article, or regulations adopted pursuant thereto, may subject the person or entity that committed the violation to a fine of up to two thousand five hundred dollars ($2,500) per occurrence pursuant to a citation issued by the board.

4127.5. Fee
This section is repealed.

4127.6. Article Operative Upon Allocation of Positions
This article shall become operative upon the allocation of positions to the board for the implementation of the provisions of this article in the annual Budget Act.

4127.7. Compounding Sterile Injectables from Nonsterile Ingredients; Requirements
On and after July 1, 2005, a pharmacy shall compound sterile injectable products from one or more nonsterile ingredients in one of the following environments:
(a) An ISO class 5 laminar airflow hood within an ISO class cleanroom. The cleanroom must have a positive air pressure differential relative to adjacent areas.
(b) An ISO class 5 cleanroom.
(c) A barrier isolator that provides an ISO class 5 environment for compounding.

4127.8. Temporary License to Compound Injectables
The board may, at its discretion, issue a temporary license to compound injectable sterile drug products, when the ownership of a pharmacy that is licensed to compound injectable sterile drug products is transferred from one person to another, upon the conditions and for any periods of time as the board determines to be in
the public interest. A temporary license fee shall be required in an amount established by the board as specified in subdivision (u) of Section 4400. When needed to protect public safety, a temporary license may be issued for a period not to exceed 180 days, and may be issued subject to terms and conditions the board deems necessary. If the board determines a temporary license was issued by mistake or denies the application for a permanent license, the temporary license shall terminate upon either personal service of the notice of termination upon the licenseholder or service by certified mail, return receipt requested at the licenseholder’s address of record with the board, whichever comes first. Neither for purposes of retaining a temporary license nor for purposes of any disciplinary or license denial proceeding before the board shall the temporary licenseholder be deemed to have a vested property right or interest in the license.
AGENDA ITEM XII
ATTACHMENT 2
Article 4.5 Compounding

1735. Compounding in Licensed Pharmacies
(a) “Compounding” means any of the following activities occurring in a licensed pharmacy, by or under the supervision of a licensed pharmacist, pursuant to a prescription:
   (1) Altering the dosage form or delivery system of a drug
   (2) Altering the strength of a drug
   (3) Combining components or active ingredients
   (4) Preparing a drug product from chemicals or bulk drug substances
(b) “Compounding” does not include reconstitution of a drug pursuant to a manufacturer’s direction(s) for oral, rectal topical, or injectable administration, nor does it include tablet splitting or the addition of flavoring agent(s) to enhance palatability.
(c) “Compounding” does not include, except in small quantities under limited circumstances as justified by a specific, documented, medical need, preparation of a compounded drug product that is commercially available in the marketplace or that is essentially a copy of a drug product that is commercially available in the marketplace.
(d) The parameters and requirements stated by this Article 4.5 (Section 1735 et seq.) apply to all compounding practices. Additional parameters and requirements applicable solely to sterile injectable compounding are stated by Article 7(Section 1735 et seq.).


1735.1. Compounding Definitions
(a) “Integrity” means retention of potency until the expiration date noted on the label.
(b) “Potency” means active ingredient strength within +/- 10% of the labeled amount.
(c) “Quality” means the absence of harmful levels of contaminants, including filth, putrid, or decomposed substances, and absence of active ingredients other than those noted on the label.
(d) “Strength” means amount of active ingredient per unit of a compounded drug product.


1735.2. Compounding Limitations and Requirements; Self-Assessment
(a) Except as specified in (b) and (c), no drug product shall be compounded prior to receipt by a pharmacy of a valid prescription for an individual patient where the prescriber has approved use of a compounded drug product either orally or in writing. Where approval is given orally, that approval shall be noted on the prescription prior to compounding.

1 See Adopted Text for proposed amendments to this section.
2 See Adopted Text for proposed amendments to this section.
(b) A pharmacy may prepare and store a limited quantity of a compounded drug product in advance of receipt of a patient-specific prescription where and solely in such quantity as is necessary to ensure continuity of care for an identified population of patients of the pharmacy based on a documented history of prescriptions for that patient population.

(c) Pursuant to Business and Professions Code section 4052(a)(1), a “reasonable quantity” of compounded drug product may be furnished to a prescriber for office use upon prescriber order, where “reasonable quantity” is that amount of compounded drug product that:

1. is sufficient for administration or application to patients in the prescriber’s office, or for distribution of not more than a 72-hour supply to the prescriber’s patients, as estimated by the prescriber; and

2. is reasonable considering the intended use of the compounded medication and the nature of the prescriber’s practice; and

3. for any individual prescriber and for all prescribers taken as a whole, is an amount which the pharmacy is capable of compounding in compliance with pharmaceutical standards for integrity, potency, quality and strength of the compounded drug product.

(d) A drug product shall not be compounded until the pharmacy has first prepared a written master formula record that includes at least the following elements:

1. Active ingredients to be used.

2. Inactive ingredients to be used.

3. Process and/or procedure used to prepare the drug.

4. Quality reviews required at each step in preparation of the drug.

5. Post-compounding process or procedures required, if any.

6. Expiration dating requirements.

(e) Where a pharmacy does not routinely compound a particular drug product, the master formula record for that product may be recorded on the prescription document itself.

(f) The pharmacist performing or supervising compounding is responsible for the integrity, potency, quality, and labeled strength of a compounded drug product until it is dispensed.

(g) All chemicals, bulk drug substances, drug products, and other components used for drug compounding shall be stored and used according to compendial and other applicable requirements to maintain their integrity, potency, quality, and labeled strength.

(h) Every compounded drug product shall be given an expiration date representing the date beyond which, in the professional judgment of the pharmacist performing or supervising the compounding, it should not be used. This “beyond use date” of the compounded drug product shall not exceed 180 days from preparation or the shortest expiration date of any component in the compounded drug product, unless a longer date is supported by stability studies of finished drugs or compounded drug products using the same components and packaging. Shorter dating than set forth in this subsection may be used if it is deemed appropriate in the professional judgment of the responsible pharmacist.

(i) The pharmacist performing or supervising compounding is responsible for the proper preparation, labeling, storage, and delivery of the compounded drug product.

(j) Prior to allowing any drug product to be compounded in a pharmacy, the pharmacist-in-charge shall complete a self-assessment form for compounding pharmacies developed by the board Form 17M-39 (Rev. 01/11). That form contains a first section applicable to all compounding, and a second section applicable to sterile injectable compounding. The first section must be completed by the pharmacist-in-charge before any compounding is performed in the pharmacy. The second section must
be completed by the pharmacist-in-charge before any sterile injectable compounding is performed in the pharmacy. The applicable sections of the self-assessment shall subsequently be completed before July 1 of odd-numbered each year, within 30 days of the start of a new pharmacist-in-charge, and within 30 days of the issuance of a new pharmacy license. The primary purpose of the self-assessment is to promote compliance through self-examination and education.

Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052, and 4127, Business and Professions Code, Sections 1735, 1735.1-.1735.8., and 1751.1-.1715.8 of Title 16 of the California Code of Regulations.

31735.3. Recordkeeping of Compounded Drug Product
(a) For each compounded drug product, the pharmacy records shall include:
   (1) The master formula record.
   (2) The date the drug product was compounded.
   (3) The identity of the pharmacy personnel who compounded the drug product.
   (4) The identity of the pharmacist reviewing the final drug product.
   (5) The quantity of each component used in compounding the drug product.
   (6) The manufacturer and lot number of each component. If the manufacturer name is demonstrably unavailable, the name of the supplier may be substituted. Exempt from the requirements in this paragraph are sterile products compounded on a one-time basis for administration within twenty-four hours to an inpatient in a health care facility licensed under section 1250 of the Health and Safety Code.
   (7) The equipment used in compounding the drug product.
   (8) A pharmacy assigned reference or lot number for the compounded drug product.
   (9) The expiration date of the final compounded drug product.
   (10) The quantity or amount of drug product compounded.
(b) Pharmacies shall maintain records of the proper acquisition, storage, and destruction of chemicals, bulk drug substances, drug products, and components used in compounding.
(c) Chemicals, bulk drug substances, drug products, and components used to compound drug products shall be obtained from reliable suppliers. The pharmacy shall acquire and retain any available certificates of purity or analysis for chemicals, bulk drug substances, drug products, and components used in compounding. Certificates of purity or analysis are not required for products that are approved by the Food and Drug Administration.
(d) Pharmacies shall maintain and retain all records required by this article in the pharmacy in a readily retrievable form for at least three years from the date the record was created.


---

3 See Adopted Text for proposed amendments to this section.
1735.4. Labeling of Compounded Drug Products
(a) In addition to the labeling information required under Business and Professions Code section 4076, the label of a compounded drug product shall contain the generic name(s) of the principal active ingredient(s).
(b) A statement that the drug has been compounded by the pharmacy shall be included on the container or on the receipt provided to the patient.
(c) Drug products compounded into unit-dose containers that are too small or otherwise impractical for full compliance with subdivisions (a) and (b) shall be labeled with at least the name(s) of the active ingredient(s), concentration of strength, volume or weight, pharmacy reference or lot number, and expiration date.


1735.5. Compounding Policies and Procedures
(a) Any pharmacy engaged in compounding shall maintain a written policy and procedure manual for compounding that establishes procurement procedures, methodologies for the formulation and compounding of drugs, facilities and equipment cleaning, maintenance, operation, and other standard operating procedures related to compounding.
(b) The policy and procedure manual shall be reviewed on an annual basis by the pharmacist-in-charge and shall be updated whenever changes in processes are implemented.
(c) The policy and procedure manual shall include the following:
   (1) Procedures for notifying staff assigned to compounding duties of any changes in processes or to the policy and procedure manual.
   (2) Documentation of a plan for recall of a dispensed compounded drug product where subsequent verification demonstrates the potential for adverse effects with continued use of a compounded drug product.
   (3) The procedures for maintaining, storing, calibrating, cleaning, and disinfecting equipment used in compounding, and for training on these procedures as part of the staff training and competency evaluation process.
   (4) Documentation of the methodology used to test integrity, potency, quality, and labeled strength of compounded drug products.
   (5) Documentation of the methodology used to determine appropriate expiration dates for compounded drug products.


1735.6. Compounding Facilities and Equipment
(a) Any pharmacy engaged in compounding shall maintain written documentation regarding the facilities and equipment necessary for safe and accurate compounded drug products. Where applicable, this shall include records of certification(s) of facilities or equipment.
(b) Any equipment used to compound drug products shall be stored, used, and maintained in accordance with manufacturers’ specifications.
(c) Any equipment used to compound drug products for which calibration or adjustment is appropriate shall be calibrated prior to use to ensure accuracy. Documentation of each such calibration shall be recorded in writing and these records of calibration shall be maintained and retained in the pharmacy.


1735.7. Training of Compounding Staff
(a) Any pharmacy engaged in compounding shall maintain written documentation sufficient to demonstrate that pharmacy personnel have the skills and training required to properly and accurately perform their assigned responsibilities relating to compounding.
(b) The pharmacy shall develop and maintain an on-going competency evaluation process for pharmacy personnel involved in compounding, and shall maintain documentation of any and all training related to compounding undertaken by pharmacy personnel.
(c) Pharmacy personnel assigned to compounding duties shall demonstrate knowledge about processes and procedures used in compounding any drug product.


1735.8. Compounding Quality Assurance
(a) Any pharmacy engaged in compounding shall maintain, as part of its written policies and procedures, a written quality assurance plan designed to monitor and ensure the integrity, potency, quality, and labeled strength of compounded drug products.
(b) The quality assurance plan shall include written procedures for verification, monitoring, and review of the adequacy of the compounding processes and shall also include written documentation of review of those processes by qualified pharmacy personnel.
(c) The quality assurance plan shall include written standards for qualitative and quantitative integrity, potency, quality, and labeled strength analysis of compounded drug products. All qualitative and quantitative analysis reports for compounded drug products shall be retained by the pharmacy and collated with the compounding record and master formula.
(d) The quality assurance plan shall include a written procedure for scheduled action in the event any compounded drug product is ever discovered to be below minimum standards for integrity, potency, quality, or labeled strength.

Article 7. Sterile Injectable Compounding

1751. Sterile Injectable Compounding; Compounding Area; Self-Assessment
(a) Any pharmacy engaged in compounding sterile injectable drug products shall conform to the parameters and requirements stated by Article 4.5 (Section 1735 et seq.), applicable to all compounding, and shall also conform to the parameters and requirements stated by this Article 7 (Section 1751 et seq.), applicable solely to sterile injectable compounding.
(b) Any pharmacy compounding sterile injectable drug products shall have a designated area for the preparation of sterile injectable products which shall meet the following standards:
   (1) Clean Room and Work Station Requirements, shall be in accordance with Section 490A.3.1 of Title 24, Part 2, Chapter 4A of the California Code of Regulations.
   (2) Walls, ceilings and floors shall be constructed in accordance with Section 490A.3 of Title 24, Part 2, Chapter 4A of the California Code of Regulations.
   (3) Be ventilated in a manner in accordance with Section 505.12 Title 24, Part 4, Chapter 5 of the California Code of Regulations.
   (4) Be certified annually by a qualified technician who is familiar with the methods and procedures for certifying laminar air flow hoods and clean room requirements, in accordance with standards adopted by the United States General Services Administration. Certification records must be retained for at least 3 years.
   (5) The pharmacy shall be arranged in accordance with Section 490A.3 of Title 24, Part 2, Chapter 4A of the California Code of Regulations. Items related to the compounding of sterile injectable products within the compounding area shall be stored in such a way as to maintain the integrity of an aseptic environment.
   (6) A sink shall be included in accordance with Section 490A.3.4 Title 24, Part 2, Chapter 4A of the California Code of Regulations.
   (7) There shall be a refrigerator and/or freezer of sufficient capacity to meet the storage requirements for all material requiring refrigeration.
(c) Any pharmacy compounding a sterile injectable product from one or more non-sterile ingredients shall comply with Business and Professions Code section 4127.7.

Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052, 4127 and 4127.7, Business and Professions Code; Sections 1735, 1735.1-, 1735.8., and 1751.1-1751.8. of Title 16 of the California Code of Regulations; and Section 18944, Health and Safety Code.

1751.1. Sterile Injectable Recordkeeping Requirements.
(a) Pharmacies compounding sterile injectable products for future use pursuant to section 1735.2 shall, in addition to those records required by section 1735.3, make and keep records indicating the name, lot number, amount, and date on which the products were provided to a prescriber.
(b) In addition to the records required by section 1735.3 and subdivision (a), for sterile products compounded from one or more non-sterile ingredients, the following records must be made and kept by the pharmacy:
   (1) The training and competency evaluation of employees in sterile product procedures.
   (2) Refrigerator and freezer temperatures.
(3) Certification of the sterile compounding environment.
(4) Other facility quality control logs specific to the pharmacy’s policies and procedures (e.g., cleaning logs for facilities and equipment).
(5) Inspection for expired or recalled pharmaceutical products or raw ingredients.
(6) Preparation records including the master work sheet, the preparation work sheet, and records of end-product evaluation results.
(c) Pharmacies shall maintain and retain all records required by this article in the pharmacy in a readily retrievable form for at least three years from the date the record was created.


1751.2. Sterile Injectable Labeling Requirements.
In addition to the labeling information required under Business and Professions Code section 4076 and section 1735.4, a pharmacy which compounds sterile products shall include the following information on the labels for those products:
(a) Telephone number of the pharmacy, except for sterile injectable products dispensed for inpatients of a hospital pharmacy.
(b) Name and concentrations of ingredients contained in the sterile injectable product.
(c) Instructions for storage and handling.
(d) All cytotoxic agents shall bear a special label which states “Chemotherapy - Dispose of Properly.”


(a) Any pharmacy engaged in compounding sterile injectable drug products shall maintain a written policy and procedure manual for compounding that includes, in addition to the elements required by section 1735.5, written policies and procedures regarding the following:
(1) Compounding, filling, and labeling of sterile injectable compounds.
(2) Labeling of the sterile injectable product based on the intended route of administration and recommended rate of administration.
(3) Equipment and supplies.
(4) Training of staff in the preparation of sterile injectable products.
(5) Procedures for handling cytotoxic agents.
(6) Quality assurance program.
(7) Record keeping requirements.
(b) The ingredients and the compounding process for each preparation must be determined in writing before compounding begins and must be reviewed by a pharmacist.
(c) Pharmacies compounding sterile injectable products shall have written policies and procedures for the disposal of infectious materials and/or materials containing cytotoxic residues. The written policies

1 See Adopted Text for proposed amendments to this section.
and procedures shall describe the pharmacy protocols for cleanups and spills in conformity with local health jurisdiction standards.

(d) Pharmacies compounding sterile injectable products from one or more non-sterile ingredients must have written policies and procedures that comply with the following:

1. All written policies and procedures shall be immediately available to all personnel involved in these activities and board inspectors.

2. All personnel involved must read the policies and procedures before compounding sterile injectable products, and any additions, revisions, and deletions to the written policies and procedures must be communicated to all personnel involved in sterile compounding.

3. Policies and procedures must address at least the following:
   (A) Competency evaluation.
   (B) Storage and handling of products and supplies.
   (C) Storage and delivery of final products.
   (D) Process validation.
   (E) Personnel access and movement of materials into and near the controlled area.
   (F) Use and maintenance of environmental control devices used to create the critical area for manipulation of sterile products (e.g., laminar-airflow workstations, biological safety cabinets, class 100 cleanrooms, and barrier isolator workstations).
   (G) Regular cleaning schedule for the controlled area and any equipment in the controlled area and the alternation of disinfectants. Pharmacies subject to an institutional infection control policy may follow that policy as it relates to cleaning schedules and the alternation of disinfectants in lieu of complying with this subdivision.
   (H) Disposal of packaging materials, used syringes, containers, and needles to enhance sanitation and avoid accumulation in the controlled area.
   (I) For sterile batch compounding, written policies and procedures must be established for the use of master formulas and work sheets and for appropriate documentation.
   (J) Sterilization.
   (K) End-product evaluation and testing.


1751.4. Facility and Equipment Standards for Sterile Injectable Compounding

(a) No sterile injectable product shall be compounded if it is known, or reasonably should be known, that the compounding environment fails to meet criteria specified in the pharmacy’s written policies and procedures for the safe compounding of sterile injectable drug products.

(b) During the preparation of sterile injectable products, access to the designated area or cleanroom must be limited to those individuals who are properly attired.

(c) All equipment used in the designated area or cleanroom must be made of a material that can be easily cleaned and disinfected.

(d) Exterior workbench surfaces and other hard surfaces in the designated area, such as walls, floors, ceilings, shelves, tables, and stools, must be disinfected weekly and after any unanticipated event that could increase the risk of contamination.
(e) Pharmacies preparing parenteral cytotoxic agents shall do so in accordance with Section 4-1106(b) of Title 24 of the California Administrative Code, requiring a laminar air flow hood. The hood must be certified annually by a qualified technician who is familiar with the methods and procedures for certifying laminar air flow hoods and cleanroom requirements, in accordance with National Sanitation Foundation Standard 49 for Class II (Laminar Flow) Biohazard Cabinetry, as revised May, 1983 (available from the National Sanitation Foundation, 3475 Plymouth Road, P.O. Box 1468, Ann Arbor, Michigan 48106, phone number (313) 769-8010) or manufacturer’s specifications, Certification records must be retained for at least three years.


1751.5. Sterile Injectable Compounding Attire.
(a) When preparing cytotoxic agents, gowns and gloves shall be worn.
(b) When compounding sterile products from one or more non-sterile ingredients the following standards must be met:
   (1) Cleanroom garb consisting of a low-shedding coverall, head cover, face mask, and shoe covers must be worn inside the designated area at all times.
   (2) Cleanroom garb must be donned and removed outside the designated area.
   (3) Hand, finger, and wrist jewelry must be eliminated. If jewelry cannot be removed then it must be thoroughly cleaned and covered with a sterile glove.
   (4) Head and facial hair must be kept out of the critical area or be covered.
   (5) Gloves made of low-shedding materials are required.
(c) The requirements of subdivision (b) do not apply if a barrier isolator is used to compound sterile injectable products from one or more non-sterile ingredients.


1751.6 Training of Sterile Injectable Compounding Staff, Patient, and Caregiver
(a) Consultation shall be available to the patient and/or primary caregiver concerning proper use of sterile injectable products and related supplies furnished by the pharmacy.
(b) The pharmacist-in-charge shall be responsible to ensure all pharmacy personnel engaging in compounding sterile injectable drug products shall have training and demonstrated competence in the safe handling and compounding of sterile injectable products, including cytotoxic agents if the pharmacy compounds products with cytotoxic agents.
(c) Records of training and demonstrated competence shall be available for each individual and shall be retained for three years beyond the period of employment.
(d) The pharmacist-in-charge shall be responsible to ensure the continuing competence of pharmacy personnel engaged in compounding sterile injectable products.
(e) Pharmacies that compound sterile products from one or more non-sterile ingredients must comply with the following training requirements:
(1) The pharmacy must establish and follow a written program of training and performance evaluation designed to ensure that each person working in the designated area has the knowledge and skills necessary to perform their assigned tasks properly. This program of training and performance evaluation must address at least the following:
   (A) Aseptic technique.
   (B) Pharmaceutical calculations and terminology.
   (C) Sterile product compounding documentation.
   (D) Quality assurance procedures.
   (E) Aseptic preparation procedures.
   (F) Proper gowning and gloving technique.
   (G) General conduct in the controlled area.
   (H) Cleaning, sanitizing, and maintaining equipment used in the controlled area.
   (I) Sterilization techniques.
   (J) Container, equipment, and closure system selection.

(2) Each person assigned to the controlled area must successfully complete practical skills training in aseptic technique and aseptic area practices. Evaluation must include written testing and a written protocol of periodic routine performance checks involving adherence to aseptic area policies and procedures. Each person’s proficiency and continuing training needs must be reassessed every 12 months. Results of these assessments must be documented and retained in the pharmacy for three years.


1751.7. Sterile Injectable Compounding Quality Assurance and Process Validation.
   (a) Any pharmacy engaged in compounding sterile injectable drug products shall maintain, as part of its written policies and procedures, a written quality assurance plan including, in addition to the elements required by section 1735.8, a documented, ongoing quality assurance program that monitors personnel performance, equipment, and facilities. The end product shall be examined on a periodic sampling basis as determined by the pharmacist-in-charge to assure that it meets required specifications. The Quality Assurance Program shall include at least the following:
      (1) Cleaning and sanitization of the parenteral medication preparation area.
      (2) The storage of compounded sterile injectable products in the pharmacy and periodic documentation of refrigerator temperature.
      (3) Actions to be taken in the event of a drug recall.
      (4) Written justification of the chosen expiration dates for compounded sterile injectable products.
   (b) Each individual involved in the preparation of sterile injectable products must first successfully complete a validation process on technique before being allowed to prepare sterile injectable products. The validation process shall be carried out in the same manner as normal production, except that an appropriate microbiological growth medium is used in place of the actual product used during sterile preparation. The validation process shall be representative of all types of manipulations, products and batch sizes the individual is expected to prepare. The same personnel, procedures, equipment, and materials must be involved. Completed medium samples must be incubated. If microbial growth is detected, then the sterile preparation process must be evaluated, corrective action
taken, and the validation process repeated. Personnel competency must be revalidated at least every twelve months, whenever the quality assurance program yields an unacceptable result, when the compounding process changes, equipment used in the compounding of sterile injectable drug products is repaired or replaced, the facility is modified in a manner that affects airflow or traffic patterns, or whenever improper aseptic techniques are observed. Revalidation must be documented.

(c) Batch-produced sterile injectable drug products compounded from one or more non-sterile ingredients shall be subject to documented end product testing for sterility and pyrogens and shall be quarantined until the end product testing confirms sterility and acceptable levels of pyrogens.

(d) Batch-produced sterile to sterile transfers shall be subject to periodic testing through process validation for sterility as determined by the pharmacist-in-charge and described in the written policies and procedures.


In any pharmacy engaged in compounding sterile injectable drug products, there shall be current and appropriate reference materials regarding the compounding of sterile injectable products located in or immediately available to the pharmacy.

AGENDA ITEM XII

ATTACHMENT 3
Amend Section 1735.1 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1735.1. Compounding Definitions.

(a) “Equipment” means items that must be calibrated, maintained or periodically certified.

(b) “Integrity” means retention of potency until the expiration date noted on the label.

(c) “Potency” means active ingredient strength within +/− 10% of the labeled amount.

(d) “Quality” means the absence of harmful levels of contaminants, including filth, putrid, or decomposed substances, and absence of active ingredients other than those noted on the label.

(e) “Strength” means amount of active ingredient per unit of a compounded drug product.

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.

Amend Section 1735.2 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1735.2. Compounding Limitations and Requirements; Self-Assessment.

(a) Except as specified in (b) and (c), no drug product shall be compounded prior to receipt by a pharmacy of a valid prescription for an individual patient where the prescriber has approved use of a compounded drug product either orally or in writing. Where approval is given orally, that approval shall be noted on the prescription prior to compounding.

(b) A pharmacy may prepare and store a limited quantity of a compounded drug product in advance of receipt of a patient-specific prescription where and solely in such quantity as is necessary to ensure continuity of care for an identified population of patients of the pharmacy based on a documented history of prescriptions for that patient population.

(c) A “reasonable quantity” as used in Business and Professions Code section 4052(a)(1) means that amount of compounded drug product that:

(1) is sufficient for administration or application to patients in the prescriber's office, or for distribution of not more than a 72-hour supply to the prescriber's patients, as estimated by the prescriber; and

(2) is reasonable considering the intended use of the compounded medication and the nature of the prescriber's practice; and

NOTE: As of December 21, 2012, this Rulemaking is under review at the Office of Administrative Law.
(3) for any individual prescriber and for all prescribers taken as a whole, is an amount which the pharmacy is capable of compounding in compliance with pharmaceutical standards for integrity, potency, quality and strength of the compounded drug product.

(d) A drug product shall not be compounded until the pharmacy has first prepared a written master formula record that includes at least the following elements:

(1) Active ingredients to be used.

(2) Equipment to be used.

(3) Expiration dating requirements.

(2) (4) Inactive ingredients to be used.

(3) (5) Process and/or procedure used to prepare the drug.

(4) (6) Quality reviews required at each step in preparation of the drug.

(5) (7) Post-compounding process or procedures required, if any.

(6) Expiration dating requirements.

(e) Where a pharmacy does not routinely compound a particular drug product, the master formula record for that product may be recorded on the prescription document itself.

(f) The pharmacist performing or supervising compounding is responsible for the integrity, potency, quality, and labeled strength of a compounded drug product until it is dispensed.

(g) All chemicals, bulk drug substances, drug products, and other components used for drug compounding shall be stored and used according to compendial and other applicable requirements to maintain their integrity, potency, quality, and labeled strength.

(h) Every compounded drug product shall be given an expiration date representing the date beyond which, in the professional judgment of the pharmacist performing or supervising the compounding, it should not be used. This “beyond use date” of the compounded drug product shall not exceed 180 days from preparation or the shortest expiration date of any component in the compounded drug product, unless a longer date is supported by stability studies of finished drugs or compounded drug products using the same components and packaging. Shorter dating than set forth in this subsection may be used if it is deemed appropriate in the professional judgment of the responsible pharmacist.

(i) The pharmacist performing or supervising compounding is responsible for the proper preparation, labeling, storage, and delivery of the compounded drug product.

(j) Prior to allowing any drug product to be compounded in a pharmacy, the pharmacist-in-charge shall complete a self-assessment for compounding pharmacies developed by the board. (Incorporated by reference is “Community Pharmacy & Hospital Outpatient Pharmacy Compounding Self-Assessment” Form 17M-39 Rev. 01/11 02/12.) That form contains a first section applicable to all compounding, and a second section applicable to sterile injectable compounding. The first section must be completed by

---

**NOTE:** As of December 21, 2012, this Rulemaking is under review at the Office of Administrative Law.
the pharmacist-in-charge before any compounding is performed in the pharmacy. The second section must be completed by the pharmacist-in-charge before any sterile injectable compounding is performed in the pharmacy. The applicable sections of the self-assessment shall subsequently be completed before July 1 of each odd-numbered year, within 30 days of the start of a new pharmacist-in-charge, and within 30 days of the issuance of a new pharmacy license. The primary purpose of the self-assessment is to promote compliance through self-examination and education.

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.

To Amend Section 1735.3 of Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

§ 1735.3. Records of Compounded Drug Products.

(a) For each compounded drug product, the pharmacy records shall include:

(1) The master formula record.

(2) The date the drug product was compounded.

(3) The identity of the pharmacy personnel who compounded the drug product.

(4) The identity of the pharmacist reviewing the final drug product.

(5) The quantity of each component used in compounding the drug product.

(6) The manufacturer, expiration date and lot number of each component. If the manufacturer name is demonstrably unavailable, the name of the supplier may be substituted. Exempt from the requirements in this paragraph are sterile products compounded on a one-time basis for administration within twenty-four, seventy-two (72) hours and stored in accordance with United States Pharmacopeia Standards for “REDISPENSED CSPs” in Chapter 797 (35th Revision, Effective May 1, 2012), which is hereby incorporated by reference, to an inpatient in a health care facility licensed under section 1250 of the Health and Safety Code.

(7) The equipment used in compounding the drug product.

(8) A pharmacy assigned reference or lot number for the compounded drug product.

(9) The expiration date of the final compounded drug product.

(10) The quantity or amount of drug product compounded.

(b) Pharmacies shall maintain records of the proper acquisition, storage, and destruction of chemicals, bulk drug substances, drug products, and components used in compounding.

(c) Chemicals, bulk drug substances, drug products, and components used to compound drug products shall be obtained from reliable suppliers. The pharmacy shall acquire and retain any available

NOTE: As of December 21, 2012, this Rulemaking is under review at the Office of Administrative Law.
certificates of purity or analysis for chemicals, bulk drug substances, drug products, and components used in compounding. Certificates of purity or analysis are not required for drug products that are approved by the Food and Drug Administration.

(d) Pharmacies shall maintain and retain all records required by this article in the pharmacy in a readily retrievable form for at least three years from the date the record was created.

Note: Authority cited: Sections 4005, 4127 and 4169, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052 and 4127, Business and Professions Code.

**To Amend Section 1751.2 of Article 7 of Division 17 of Title 16 to read as follows:**

§ 1751.2. Sterile Injectable Labeling Requirements.

In addition to the labeling information required under Business and Professions Code section 4076 and section 1735.4, a pharmacy which compounds sterile injectable products shall include the following information on the labels for those products:

(a) Telephone number of the pharmacy, except for sterile injectable products dispensed for inpatients of a hospital pharmacy.

(b) Name and concentrations of ingredients contained in the sterile injectable product.

(c) Instructions for storage and handling.

(d) All cytotoxic agents shall bear a special label which states “Chemotherapy - Dispose of Properly;” or “Cytotoxic Product – Dispose of Properly.”

Note: Authority cited: Sections 4005 and 4127, Business and Professions Code. Reference: Sections 4005, 4036, 4037, 4051, 4052, 4076 and 4127, Business and Professions Code.

---

**NOTE: As of December 21, 2012, this Rulemaking is under review at the Office of Administrative Law.**
Article 7.5. Injectable Sterile Drug Products

4127.
The board shall adopt regulations establishing standards for compounding injectable sterile drug products in a pharmacy. A pharmacy that compounds sterile drug products for injection, for administration into eyes, or for inhalation, shall be required to possess a sterile compounding license as provided for under this article before dispensing any such compounded medication.

4127.1.
(a) A pharmacy shall not compound injectable sterile drug products in this state unless the pharmacy has obtained a license from the board pursuant to this section. The license shall be renewed annually and is not transferable.

(b) A license to compound injectable sterile drug products may only be issued for to a location that is licensed as a pharmacy. Furthermore, the license to compound injectable sterile drug products may only be issued to the owner of the pharmacy licensed at that location. A license to compound injectable sterile drug products may not be issued until the location is inspected by the board and found in compliance with this article and regulations adopted by the board.

(c) A license to compound injectable sterile drug products may not be issued or renewed until the location has been inspected by the board; and found to be in compliance with this article and regulations adopted by the board.

(1) performs an onsite inspection of the premises, and is assured that any deficiencies noted are corrected.

(2) reviews a current copy of the pharmacy's proposed policies and procedures for sterile compounding.

(3) reviews the pharmacy's completed self-assessment form required by section 1735.2 of Title 16 of the California Code of Regulations.

(4) is provided with copies of all inspection reports conducted of the pharmacy’s premises or reports from a private accrediting agency conducted in the prior 12 months documenting the pharmacy’s operations.

(5) receives a list of all sterile medications compounded by the pharmacy since the last license renewal.
(d) A pharmacy licensed pursuant to this section must provide the board within 10 days copies of any disciplinary or other action taken by any other state. The pharmacy shall notify the board within 10 days of a suspension of any accreditation it may possess.

(e) A pharmacy licensed pursuant to this section shall provide the board, within 24 hours, any recall notice issued by the pharmacy for sterile drug products it has compounded.

(f) Adverse effects reported or potentially attributable to a nonresident pharmacy's products shall be immediately reported to MedWatch and to the board.

---

(d) Pharmacies operated by entities that are licensed by either the board or the State Department of Public Health and that have current accreditation from the Joint Commission on Accreditation of Healthcare Organizations, or other private accreditation agencies approved by the board, are exempt from the requirement to obtain a license pursuant to this section.

---

(e) (g) The reconstitution of a sterile powder shall not require a license pursuant to this section if both of the following are met:

1. The sterile powder was obtained from a manufacturer.
2. The drug is reconstituted for administration to patients by a health care professional licensed to administer drugs by injection pursuant to this section.

4127.2. Nonresident Pharmacy

(a) A nonresident pharmacy may not compound injectable sterile drug products for shipment into the State of California without a license issued by the board pursuant to this section. The license shall be renewed annually and shall not be transferable.

(b) A license to compound injectable sterile drug products may only be issued for a location that is licensed as a nonresident pharmacy. Furthermore, the license to compound injectable sterile drug products may only be issued to the owner of the nonresident pharmacy license licensed at that location. A license to compound sterile drug products may not be issued until the location is inspected by the board and found in compliance with this article and regulations adopted by the board.

(c) A license to compound injectable sterile drug products may not be issued or renewed until the board:

1. Performs an onsite inspection of the premises, and is assured that any deficiencies noted are corrected.
2. Reviews a current copy of the nonresident pharmacy's proposed policies and procedures for sterile compounding.
3. Reviews the pharmacy's completed self-assessment form required by section 1735.2 of Title 16 of the California Code of Regulations.
(4) is provided with copies of all inspection reports conducted of the pharmacy’s premises or 
reports from a private accrediting agency conducted in the prior 12 months documenting the 
pharmacy’s operations.
(5) receives a list of all sterile medications compounded by the pharmacy and shipped into 
California. 
(d) A nonresident pharmacy licensed pursuant to this section must provide the board within 
10 days copies of any disciplinary or other action taken by the resident or any other state. The 
nonresident pharmacy shall also notify the board within 10 days of a suspension of any 
accreditation it may possess.
(e) A nonresident pharmacy licensed pursuant to this section shall provide the board, within 
24 hours, any recall notice issued by the pharmacy for sterile drug products that have been 
shipped or dispensed into California.
(f) A nonresident pharmacy licensed pursuant to this section shall advise the board of any 
complaint it receives from a provider, pharmacy or patient in California.
(g) Adverse effects reported or potentially attributable to a nonresident pharmacy’s products 
shall be immediately reported to MedWatch and to the board.

(1) a copy of an inspection report issued by the pharmacy’s licensing agency or a report from a 
private accrediting agency approved by the board, in the prior 12 months documenting the 
pharmacy’s compliance with board regulations regarding the compounding of injectable sterile 
drug products.
—(2) A copy of the nonresident pharmacy’s proposed policies and procedures for sterile 
compounding.
—(c) Nonresident pharmacies operated by entities that are licensed as a hospital, home health 
agency, or a skilled nursing facility and have current accreditation from the Joint Commission on 
Accreditation of Healthcare Organizations, or other private accreditation agencies approved by 
the board, are exempt from the requirement to obtain a license pursuant to this section.
—(d) This section shall become effective on the earlier of July 1, 2003, or the effective date of 
regulations adopted by the board pursuant to Section 4127.

4400. Fees
The amount of fees and penalties prescribed by this chapter, except as otherwise provided is 
that fixed by the board according to the following schedule:
(a) The fee for a nongovernmental pharmacy license shall be four hundred dollars ($400) and 
may be increased to five hundred twenty dollars ($520). The fee for the issuance of a
temporary nongovernmental pharmacy permit shall be two hundred fifty dollars ($250) and may be increased to three hundred twenty-five dollars ($325).

(b) The fee for a nongovernmental pharmacy license annual renewal shall be two hundred fifty dollars ($250) and may be increased to three hundred twenty-five dollars ($325).

(c) The fee for the pharmacist application and examination shall be two hundred dollars ($200) and may be increased to two hundred sixty dollars ($260).

(d) The fee for regrading an examination shall be ninety dollars ($90) and may be increased to one hundred fifteen dollars ($115). If an error in grading is found and the applicant passes the examination, the regrading fee shall be refunded.

(e) The fee for a pharmacist license and biennial renewal shall be one hundred fifty dollars ($150) and may be increased to one hundred ninety-five dollars ($195).

(f) The fee for a nongovernmental wholesaler license and annual renewal shall be six hundred dollars ($600) and may be increased to seven hundred eighty dollars ($780). The application fee for any additional location after licensure of the first 20 locations shall be two hundred twenty-five dollars ($225) and may be increased to three hundred dollars ($300). A temporary license fee shall be five hundred fifty dollars ($550) and may be increased to seven hundred fifteen dollars ($715).

(g) The fee for a hypodermic license and renewal shall be one hundred twenty-five dollars ($125) and may be increased to one hundred sixty-five dollars ($165).

(h) (1) The fee for application, investigation, and issuance of license as a designated representative pursuant to Section 4053 shall be two hundred fifty-five dollars ($255) and may be increased to three hundred thirty dollars ($330).

(2) The fee for the annual renewal of a license as a designated representative shall be one hundred fifty dollars ($150) and may be increased to one hundred ninety-five dollars ($195).

(i) (1) The fee for the application, investigation, and issuance of a license as a designated representative for a veterinary food-animal drug retailer pursuant to Section 4053 shall be two hundred fifty-five dollars ($255) and may be increased to three hundred thirty dollars ($330).

(2) The fee for the annual renewal of a license as a designated representative for a veterinary food-animal drug retailer shall be one hundred fifty dollars ($150) and may be increased to one hundred ninety-five dollars ($195).

(j) (1) The application fee for a nonresident wholesaler’s license issued pursuant to Section 4161 shall be six hundred dollars ($600) and may be increased to seven hundred eighty dollars ($780).

(2) For nonresident wholesalers who have 21 or more facilities operating nationwide the application fees for the first 20 locations shall be six hundred dollars ($600) and may be increased to seven hundred eighty dollars ($780). The application fee for any additional location...
after licensure of the first 20 locations shall be two hundred twenty-five dollars ($225) and may
be increased to three hundred dollars ($300). A temporary license fee shall be five hundred fifty
dollars ($550) and may be increased to seven hundred fifteen dollars ($715).

(3) The annual renewal fee for a nonresident wholesaler’s license issued pursuant to
Section 4161 shall be six hundred dollars ($600) and may be increased to seven hundred eighty
dollars ($780).

(k) The fee for evaluation of continuing education courses for accreditation shall be set by the
board at an amount not to exceed forty dollars ($40) per course hour.

(l) The fee for an intern pharmacist license shall be ninety dollars ($90) and may be increased to
one hundred fifteen dollars ($115). The fee for transfer of intern hours or verification of
licensure to another state shall be twenty-five dollars ($25) and may be increased to thirty
dollars ($30).

(m) The board may waive or refund the additional fee for the issuance of a license where the
license is issued less than 45 days before the next regular renewal date.

(n) The fee for the reissuance of any license, or renewal thereof, that has been lost or destroyed
or reissued due to a name change shall be thirty-five dollars ($35) and may be increased to
forty-five dollars ($45).

(o) The fee for the reissuance of any license, or renewal thereof, that must be reissued because
of a change in the information, shall be one hundred dollars ($100) and may be increased to
one hundred thirty dollars ($130).

(p) It is the intent of the Legislature that, in setting fees pursuant to this section, the board shall
seek to maintain a reserve in the Pharmacy Board Contingent Fund equal to approximately one
year’s operating expenditures.

(q) The fee for any applicant for a nongovernmental clinic license shall be four hundred dollars
($400) and may be increased to five hundred twenty dollars ($520) for each license. The annual
fee for renewal of the license shall be two hundred fifty dollars ($250) and may be increased to
three hundred twenty-five dollars ($325) for each license.

(r) The fee for the issuance of a pharmacy technician license shall be eighty dollars ($80) and
may be increased to one hundred five dollars ($105). The fee for renewal of a pharmacy
technician license shall be one hundred dollars ($100) and may be increased to one hundred
thirty dollars ($130).

(s) The fee for a veterinary food-animal drug retailer license shall be four hundred five dollars
($405) and may be increased to four hundred twenty-five dollars ($425). The annual renewal
fee for a veterinary food-animal drug retailer license shall be two hundred fifty dollars ($250)
and may be increased to three hundred twenty-five dollars ($325).
(t) The fee for issuance of a retired license pursuant to Section 4200.5 shall be thirty-five dollars ($35) and may be increased to forty-five dollars ($45).

(u) The fee for issuance or renewal of a nongovernmental license to compound sterile drug products shall be six hundred dollars ($600) and may be increased to seven hundred eighty dollars ($780). The fee for a temporary license shall be five hundred fifty dollars ($550) and may be increased to seven hundred fifteen dollars ($715).

(v) The fee for a nonresident sterile compounding pharmacy license shall also require payment of the travel expenses incurred by the board in inspecting the pharmacy at least once annually. Failure to pay this fee within 30 days shall result in the suspension of the nonresident pharmacy license.